Development of pulmonary hypertension in an infant treated with diazoxide.
Diazoxide is commonly used in the treatment of neonatal hyperinsulinism. We describe a one month-old infant who was treated with diazoxide for prolonged neonatal hyperinsulinism. Shortly after starting diazoxide, she was admitted to the hospital for tachypnea with hypoxemia, and was subsequently diagnosed with laryngomalacia and obstructive apnea. During hospitalization, her clinical course worsened due to the development of severe pulmonary hypertension, presumed due to diazoxide toxicity. Lung biopsy revealed a probable toxic vascular drug reaction. After discontinuing diazoxide, her clinical status improved and eventually returned to baseline.
Nebesio
Todd D
TD
Department of Pediatrics, Sections of Pediatric Endocrinology/Diabetology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN 46202, USA. tdnebesi@iupui.edu
Hoover
Wynton C
WC
Caldwell
Randall L
RL
Nitu
Mara E
ME
Eugster
Erica A
EA
D003981:Diazoxide / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000188:drug therapy*; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000628:therapy; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007223:Infant; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000097:blood; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D003981:Diazoxide